2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction

Overview

Journal Korean Circ J

Date 2020 Sep 24

PMID 32969206

Citations 11

Authors

Hyun Kuk Kim

Youngkeun Ahn

Kiyuk Chang

Young Hoon Jeong

Joo Yong Hahn

Eun Ho Choo

Min Chul Kim

Hyo Soo Kim

Weon Kim

Myeong Chan Cho

Yangsoo Jang

Chong Jin Kim

Myung Ho Jeong

Shung Chull Chae

Affiliations

Soon will be listed here.

Abstract

Clinical practice guidelines published by the European Society of Cardiology and the American College of Cardiology/American Heart Association summarize the available evidence and provide recommendations for health professionals to enable appropriate clinical decisions and improve clinical outcomes for patients with acute myocardial infarction (AMI). However, most current guidelines are based on studies in non-Asian populations in the pre-percutaneous coronary intervention (PCI) era. The Korea Acute Myocardial Infarction Registry is the first nationwide registry to document many aspects of AMI from baseline characteristics to treatment strategies. There are well-organized ongoing and published randomized control trials especially for antiplatelet therapy among Korean patients with AMI. Here, members of the Task Force of the Korean Society of Myocardial Infarction review recent published studies during the current PCI era, and have summarized the expert consensus for the pharmacotherapy of AMI.

Citing Articles

2024 Korean Society of Myocardial Infarction/National Evidence-Based Healthcare Collaborating Agency Guideline for the Pharmacotherapy of Acute Coronary Syndromes.

Kim H, Ryoo S, Lee S, Hwang D, Choi K, Park J Korean Circ J. 2024; 54(12):767-793.

PMID: 39434369 PMC: 11685345. DOI: 10.4070/kcj.2024.0257.

Ten-year trends in lipid management among patients after myocardial infarction in South Korea.

Oh S, Cho K, Kim M, Sim D, Hong Y, Kim J PLoS One. 2024; 19(10):e0304710.

PMID: 39361921 PMC: 11449489. DOI: 10.1371/journal.pone.0304710.

Proton Pump Inhibitor for Gastrointestinal Bleeding in Patients with Myocardial Infarction on Dual-Antiplatelet Therapy: A Nationwide Cohort Study.

Baik M, Jeon J, Kim J, Yoo J J Epidemiol Glob Health. 2024; 14(3):1142-1151.

PMID: 38913256 PMC: 11442791. DOI: 10.1007/s44197-024-00267-9.

Identifying and Solving Gaps in Pre- and In-Hospital Acute Myocardial Infarction Care in Asia-Pacific Countries.

Tern P, Vaswani A, Yeo K Korean Circ J. 2023; 53(9):594-605.

PMID: 37653695 PMC: 10475691. DOI: 10.4070/kcj.2023.0169.

Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.

Li J, Wang Q, Wu C, Qu X, Zhang L, He X Cardiology. 2023; 148(4):363-373.

PMID: 37094558 PMC: 10614237. DOI: 10.1159/000530602.

References

Antman E, Morrow D, McCabe C, Murphy S, Ruda M, Sadowski Z . Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006; 354(14):1477-88. DOI: 10.1056/NEJMoa060898. View

Mo C, Sun G, Lu M, Zhang L, Wang Y, Sun X . Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015; 21(17):5382-92. PMC: 4419080. DOI: 10.3748/wjg.v21.i17.5382. View

Sim D, Jeong M, Ahn Y, Kim Y, Chae S, Hong T . Safety and benefit of early elective percutaneous coronary intervention after successful thrombolytic therapy for acute myocardial infarction. Am J Cardiol. 2009; 103(10):1333-8. DOI: 10.1016/j.amjcard.2009.01.339. View

Ji M, Jeong M, Ahn Y, Kim S, Kim Y, Chae S . Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis. Int J Cardiol. 2016; 225:50-59. DOI: 10.1016/j.ijcard.2016.09.082. View

Bonnefoy E, Steg P, Boutitie F, Dubien P, Lapostolle F, Roncalli J . Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J. 2009; 30(13):1598-606. DOI: 10.1093/eurheartj/ehp156. View

Nabel E, Braunwald E . A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012; 366(1):54-63. DOI: 10.1056/NEJMra1112570. View

Jeong Y, Smith Jr S, Gurbel P . Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015; 373(13):1273-4. DOI: 10.1056/NEJMc1508692. View

Lee C, Ahn J, Park D, Kang S, Lee S, Kim Y . Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2013; 129(3):304-12. DOI: 10.1161/CIRCULATIONAHA.113.003303. View

Schupke S, Neumann F, Menichelli M, Mayer K, Bernlochner I, Wohrle J . Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381(16):1524-1534. DOI: 10.1056/NEJMoa1908973. View

10.

Ibanez B, James S, Agewall S, Antunes M, Bucciarelli-Ducci C, Bueno H . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European.... Eur Heart J. 2017; 39(2):119-177. DOI: 10.1093/eurheartj/ehx393. View

11.

Keeley E, Boura J, Grines C . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. View

12.

Mehta R, Chen A, Alexander K, Ohman E, Roe M, Peterson E . Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. Circulation. 2015; 131(11):980-7. DOI: 10.1161/CIRCULATIONAHA.114.013451. View

13.

Andersen H, Nielsen T, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P . A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003; 349(8):733-42. DOI: 10.1056/NEJMoa025142. View

14.

Roolvink V, Ibanez B, Ottervanger J, Pizarro G, van Royen N, Mateos A . Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016; 67(23):2705-2715. DOI: 10.1016/j.jacc.2016.03.522. View

15.

Park K, Jeong M, Kim H, Ahn T, Seung K, Oh D . Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization. J Cardiol. 2017; 71(1):36-43. DOI: 10.1016/j.jjcc.2017.05.003. View

16.

. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2(8607):349-60. View

17.

Korhonen M, Robinson J, Annis I, Hickson R, Bell J, Hartikainen J . Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. J Am Coll Cardiol. 2017; 70(13):1543-1554. PMC: 5890809. DOI: 10.1016/j.jacc.2017.07.783. View

18.

Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz J, Garcia-Alvarez A . Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). J Am Coll Cardiol. 2014; 63(22):2356-62. DOI: 10.1016/j.jacc.2014.03.014. View

19.

Lee J, Bae M, Yang D, Park H, Cho Y, Lee W . Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction. Korean J Intern Med. 2015; 31(2):267-76. PMC: 4773713. DOI: 10.3904/kjim.2014.268. View

20.

Choi I, Park I, Lee K, Ahn T, Kim J, Ahn Y . Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge. J Cardiovasc Pharmacol Ther. 2018; :1074248418795897. DOI: 10.1177/1074248418795897. View